MorphoSys AG (MOR.DE)

67,85 +0,10 (+0,15%) Alla chiusura: 05:36PM CEST

MorphoSys AG

Semmelweisstrasse 7
Planegg 82152
Germany
49 89 899 27-0
https://www.morphosys.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 524

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Jean-Paul Kress M.D.	Chairman of Management Board, MD & CEO	1,76M	N/D	1965
Dr. Lucinda Crabtree Ph.D.	CFO & Member of Management Board	705,82k	N/D	1979
Ms. Charlotte Lohmann	Chief Legal and Human Resources Officer & Member of Management Board	474,1k	N/D	1970
Mr. Klaus De Wall	Head of Accounting & Tax	N/D	N/D	N/D
Dr. Margit Urban	Head of Discovery Alliances & Technologies	N/D	N/D	N/D
Dr. Julia Neugebauer Ph.D.	Head of Investor Relations	N/D	N/D	N/D
Dr. Barbara Krebs-Pohl Ph.D.	Chief Business Officer	N/D	N/D	N/D
Dr. Günter Wellnhofer	Head of Technical Operations	N/D	N/D	N/D
Dr. Harald Watzka	Head of Alliance Management	N/D	N/D	N/D
Ms. Yen Ching Chua	Head of Clinical Operations	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.

Governance aziendale

L'ISS Governance QualityScore di MorphoSys AG al 1 aprile 2024 è 2. I criteri di valutazione fondamentali sono revisione: 2; Consiglio di Amministrazione: 1; diritti degli azionisti: 1; retribuzione: 6.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.